2021
Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: An individual patient data meta‐analysis
McAlpine JN, Chiu DS, Nout RA, Church DN, Schmidt P, Lam S, Leung S, Bellone S, Wong A, Brucker SY, Lee CH, Clarke BA, Huntsman DG, Bernardini MQ, Ngeow J, Santin AD, Goodfellow P, Levine DA, Köbel M, Kommoss S, Bosse T, Gilks CB, Talhouk A. Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: An individual patient data meta‐analysis. Cancer 2021, 127: 2409-2422. PMID: 33793971, DOI: 10.1002/cncr.33516.Peer-Reviewed Original ResearchConceptsIndividual patient dataEndometrial cancerPOLE mutationsAdjuvant treatmentAdverse eventsSalvage rateClinical outcomesMeta-analyses (PRISMA) reporting guidelinesConcerns of overtreatmentPathogenic POLE mutationsPatient dataEvidence of diseaseRecurrence/progressionTraditional prognostic factorsProgression/recurrenceUnfavorable pathological featuresAssociation of treatmentMixed effects Cox modelPreferred Reporting ItemsAdditional therapyAdjuvant therapyLess therapyPrognostic factorsFirst diagnosisPathological features
1998
Routine Lymph Node Dissection in the Treatment of Early Stage Cancer:Are We Doing the Right Thing?
Santin A, Parham G. Routine Lymph Node Dissection in the Treatment of Early Stage Cancer:Are We Doing the Right Thing? Gynecologic Oncology 1998, 68: 1-3. PMID: 9454650, DOI: 10.1006/gyno.1997.4900.Peer-Reviewed Original ResearchConceptsLymph node dissectionNode dissectionLymph nodesProphylactic lymph node dissectionRoutine lymph node dissectionRegional lymph nodesRecent immunological studiesTreatment of patientsEarly-stage solid tumorsEarly-stage cancerEarly-stage malignanciesManagement of cancerElective lymphadenectomyTherapeutic dissectionAntitumor reactivitySalvage rateBloc resectionSurgical interventionPrimary tumorRegional nodesStage cancerLymphatic pathwaysMatter of controversySolid tumorsImmune system